Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$104.0K+16.70%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mani Mohindru
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 31
- Beta
- 1.46
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -14.87
Financials
Revenue
$104.0K+16.7%Net Income
$-9.23MEBITDA
$-9.06MFree Cash Flow
$-11.81MEPS (diluted)
$-0.14Shares Outstanding (diluted)
68.40M+16131.5%Operating Expenses
$9.72MCash & Debt
$34.52MReturn of Capital
$0.00Revenue by Segment (annual)
$366.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $593.0K | $-45.85M | $-0.69 |
| 2024 | $683.0K | $-45.43M | $-0.95 |
| 2023 | $488.0K | $-41.44M | $-0.93 |
| 2022 | $386.0K | $-38.70M | $-0.89 |
| 2021 | $359.0K | $-28.29M | $-0.73 |
| 2020 | $366.0K | $-19.31M | $-1.08 |
| 2019 | $244.6K | $-16.41M | $-2.70 |
| 2018 | $378.0K | $-16.46M | $-7.06 |
| 2017 | $505.0K | $-24.91M | $-51.71 |
| 2016 | $381.0K | $-39.20M | $-93.54 |
| 2015 | $313.0K | $-27.47M | $-75.49 |
| 2014 | $280.0K | $-14.32M | $-54.56 |
| 2013 | $259.2K | $-11.81M | $-50.27 |
| 2012 | $450.0K | $-11.57M | $-63.87 |
Valuation
CRDFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·22d ago·Neutral
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l.
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Cardiff Oncology to Participate in September 2026 Conferences SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.14 per share
Typical surprise -5.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.14 vs $-0.12miss
- Thu, May 14$-0.18 vs $-0.13miss
- Tue, Feb 24$-0.11 vs $-0.18beat
- Thu, Nov 6$-0.17 vs $-0.20beat
- Tue, Jul 29$-0.21 vs $-0.19miss
- Thu, May 8$-0.20 vs $-0.19miss
Estimates and results for CRDF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CRDF officers and directors.
- Bought
- $4.2m
- Sold
- —
23 trades
0 trades
- Pace Gary Wbought
- Pace Gary Wbought
- Mohindru Manibought
- Mohindru Manibought
- Mohindru Manibought
- Pace Gary Wbought
- Pace Gary Wbought
- Pace Gary Wbought
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CRDF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.